Negron v. Cigna Health and Life Insurance Company

CourtDistrict Court, D. Connecticut
DecidedMarch 27, 2023
Docket3:16-cv-01702
StatusUnknown

This text of Negron v. Cigna Health and Life Insurance Company (Negron v. Cigna Health and Life Insurance Company) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Negron v. Cigna Health and Life Insurance Company, (D. Conn. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

KIMBERLY A. NEGRON et al., Plaintiffs,

v. No. 3:16-cv-1702 (JAM)

CIGNA HEALTH AND LIFE INSURANCE COMPANY, Defendant.

ORDER GRANTING MOTION FOR PARTIAL SUMMARY JUDGMENT

The plaintiffs are several individuals who had employee health insurance plans administered by Cigna Health and Life Insurance Company (“Cigna”). They allege that Cigna overcharged them for prescription drugs and that it effectuated this scheme through its use of two third-party vendors, Argus Health Systems, Inc. (“Argus”) and OptumRx, Inc. (“Optum”). Cigna has moved for summary judgment on the plaintiffs’ two claims brought under the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1961 et seq. I will grant Cigna’s motion because the plaintiffs do not allege that Argus or Optum had or shared a common fraudulent purpose and also because the evidence does not establish a genuine fact issue to show that Cigna conducted or participated in the conduct of the affairs of either Argus or Optum. BACKGROUND The plaintiffs had employee health insurance plans administered by Cigna.1 Some Cigna plans include prescription drug coverage and provide access to a network of retail pharmacies for

1 Doc. #427-2 at 2–5 (¶¶ 5, 7, 9, 11, 13); Doc. #436 at 4 (¶ 5), 5 (¶ 7), 7 (¶ 9), 9 (¶ 11), 10 (¶ 13). Most of the citations in this part of the ruling are to the parties’ respective statements of material facts. See Doc. #427-2 (Cigna’s statement of material facts); Doc. #436 (plaintiffs’ statement of material facts). I deem those facts as set forth by Cigna to be true to the extent that they are admitted by the plaintiffs. I also deem those facts as set forth by Cigna to be true to the extent that the plaintiffs admit them but add argumentative qualifiers or limitations that are not germane to the facts asserted by Cigna. See D. Conn. L. Civ. R. 56(a). plan members to fill their prescriptions.2 Cigna contracted with two pharmacy benefit managers (“PBMs”), Argus and Optum, to function as intermediaries between Cigna and the pharmacies.3 Cigna used Argus for claims processing and Optum for its network of retail pharmacies.4 Cigna, Argus, and Optum are separate companies, and the contracts between Cigna and the PBMs refer to the parties as independent contractors with one another.5

Under the Cigna-PBM contracts, when a plan member presented her prescription to an Optum network pharmacy, Argus calculated how much the member must pay pursuant to criteria provided by Cigna (what the plaintiffs term “adjudication logic”).6 Then, Argus funded part of the transaction at the point of sale, and Cigna reimbursed Argus.7 Finally, Optum remitted part of the amount received by the pharmacy back to Cigna.8 The contracts provide that Cigna alone determined how much to charge plan members.9 Neither Argus nor Optum kept any portion of the remitted charges.10 The plaintiffs characterize these remittances to Cigna, which they refer to as “clawbacks,” as illegal overcharges because their pharmacies charged more for prescription drugs than the plaintiffs were required to pay under their insurance plans.11

2 Doc. #427-2 at 1–2 (¶¶ 2–3); Doc. #436 at 2–3 (¶¶ 2–3). 3 Doc. #427-2 at 6 (¶ 17), 9 (¶ 29); Doc. #435 at 9; Doc. #436 at 12 (¶ 17), 17 (¶ 29). 4 Doc. #427-2 at 6 (¶¶ 17–18), 9 (¶ 29); Doc. #436 at 12 (¶¶ 17–18), 17 (¶ 29), 24 (¶¶ 1–3, 5), 26 (¶ 13). 5 Doc. #427-2 at 6–7 (¶¶ 16, 20), 9 (¶ 31). The plaintiffs deny that an independent contractor relationship existed between Cigna and the PBMs, but they do not dispute that the contract language refers to the parties as independent contractors. Doc. #436 at 12 (¶ 16), 13 (¶ 20), 18 (¶ 31); see also Doc. #198 at 88 (¶ 268) (second amended complaint alleging that Cigna is “legally and factually distinct from OptumRx and from Argus.”). 6 Doc. #435 at 9; Doc. #436 at 24 (¶ 5), 26–27 (¶ 17); see also Doc. #432-2 at 6–7 (deposition testimony from Cigna employee describing the prescription drug payment process). 7 Doc. #432-2 at 7, 12. 8 Doc. #436 at 24 (¶ 2), 27 (¶ 18); see, e.g., Doc. #436 at 29 (¶ 34) (“In one of Plaintiff Negron’s transactions, Cigna required Argus to adjudicate and required Optum, through its network pharmacy, to collect a copayment of $10.00, even though the pharmacy was only being paid $6.06 for that prescription drug, resulting in a $3.94 ‘clawback.’”). 9 Doc. #436 at 24 (¶¶ 4–6), 25 (¶ 8), 26 (¶ 11). 10 Doc. #427-2 at 8 (¶ 23), 10 (¶ 36); Doc. #436 at 14 (¶ 23), 20 (¶ 36). 11 Doc. #435 at 7–8. The plaintiffs’ second amended complaint—the current operative complaint—alleges several state and federal claims against Cigna on this basis, including two RICO claims: a substantive RICO claim under 18 U.S.C. § 1962(c) (Count VII) and a RICO conspiracy claim under § 1962(d) (Count VIII).12 Cigna has moved for summary judgment on both RICO claims.13 The plaintiffs withdrew

the RICO conspiracy claim in response to Cigna’s motion, leaving only the substantive RICO claim for the Court’s consideration.14 DISCUSSION The principles governing review of a motion for summary judgment are well established. Summary judgment may be granted only if “the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed R. Civ. P. 56(a). I must view the facts in the light most favorable to the party who opposes the motion for summary judgment and then decide if those facts would be enough—if eventually proved at trial—to allow a reasonable jury to decide the case in favor of the opposing party. My role at

summary judgment is not to judge the credibility of witnesses or to resolve close contested issues of fact but solely to decide if there are enough facts that remain in dispute to warrant a trial. See generally Tolan v. Cotton, 572 U.S. 650, 656–57 (2014) (per curiam); Benzemann v. Houslanger & Assocs., PLLC, 924 F.3d 73, 78 (2d Cir. 2019).15 RICO makes it “unlawful for any person employed by or associated with any enterprise engaged in, or the activities of which affect, interstate or foreign commerce, to conduct or

12 Doc. #198 at 88–101 (¶¶ 261–301). 13 Doc. #422. 14 Doc. #435 at 9 n.2. 15 Unless otherwise indicated, this order omits internal quotation marks, alterations, citations, and footnotes in text quoted from court decisions. participate, directly or indirectly, in the conduct of such enterprise’s affairs through a pattern of racketeering activity.” 18 U.S.C. § 1962(c).16 A separate RICO provision—18 U.S.C. § 1964(c)—affords a private right of action for any person who has been injured in his business or property by reason of a violation of § 1962.

To prevail on a § 1962(c) claim, the plaintiffs must show “(1) conduct (2) of an enterprise (3) through a pattern (4) of racketeering activity.” Kim v. Kimm, 884 F.3d 98, 103 (2d Cir. 2018). As a threshold matter, there must be a distinction between the “person” (here, defendant Cigna) who is alleged to have violated § 1962 and the “enterprise” through which the violation has occurred. A plaintiff “must allege and prove the existence of two distinct entities: (1) a ‘person’; and (2) an ‘enterprise’ that is not simply the same ‘person’ referred to by a different name.” U1it4less, Inc. v. FedEx Corp., 871 F.3d 199, 205 (2d Cir. 2017).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hemi Group, LLC v. City of New York
559 U.S. 1 (Supreme Court, 2010)
City of New York v. Smokes-Spirits. Com, Inc.
541 F.3d 425 (Second Circuit, 2008)
Reves v. Ernst & Young
507 U.S. 170 (Supreme Court, 1993)
Catholic Healthcare West v. US Foodservice Inc.
729 F.3d 108 (Second Circuit, 2013)
Crichton v. Golden Rule Insurance
576 F.3d 392 (Seventh Circuit, 2009)
Fuji Photo Film U.S.A., Inc. v. McNulty
640 F. Supp. 2d 300 (S.D. New York, 2009)
131 Main Street Associates v. Manko
897 F. Supp. 1507 (S.D. New York, 1995)
Lockheed Martin Corp. v. Boeing Company
357 F. Supp. 2d 1350 (M.D. Florida, 2005)
Allstate Insurance v. Seigel
312 F. Supp. 2d 260 (D. Connecticut, 2004)
City of New York v. Smokes-Spirits.Com, Inc.
911 N.E.2d 834 (New York Court of Appeals, 2009)
Tolan v. Cotton
134 S. Ct. 1861 (Supreme Court, 2014)
D'Addario v. D'Addario
901 F.3d 80 (Second Circuit, 2018)
Benzemann v. Houslanger & Assocs., PLLC
924 F.3d 73 (Second Circuit, 2019)
4 K & D Corp. v. Concierge Auctions, LLC
2 F. Supp. 3d 525 (S.D. New York, 2014)
Faryniarz v. Ramirez
62 F. Supp. 3d 240 (D. Connecticut, 2014)
Duramax Diesel Litig. Andrei Fenner v. Gen. Motors, LLC
298 F. Supp. 3d 1037 (E.D. Michigan, 2018)
Negron v. Cigna Health & Life Ins. & Optumrx, Inc.
300 F. Supp. 3d 341 (D. Connecticut, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Negron v. Cigna Health and Life Insurance Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/negron-v-cigna-health-and-life-insurance-company-ctd-2023.